List view / Grid view
Oncology is a branch of medicine that deals with the prevention, diagnosis and treatment of cancer.
Studies have identified that the TPX2 protein recruits the molecular machinery required for the branching microtubule nucleation process, so could be a target for cancer therapies.
Research into the role of non-coding DNA in cancer development and progression has identified 30 regions that may contribute to tumour growth, which could be therapeutic targets.
Researchers investigating childhood leukaemia have discovered that increasing MLL gene expression in iPSCs drives hematopoietic stem cell production, so could be the target of new therapies.
A new study shows that the VISTA molecule stops the immune system responding to self-antigens, including those presented by cancer cells, so an anti-VISTA antibody could be a possible therapy.
A study has shown that long non-coding RNA called DIRC3 can block melanoma growth and could be used to identify new targets for skin cancer therapies.
Oncologic stem cells have been identified in many malignancies, and targeting these cells could help in the fight against cancer. Here are five of the most recent findings regarding cancer stem cells.
Research indicates that activation of the RICTOR/mTORC2 pathway advances cancer metastasis and suggests that inhibiting this signalling may make chemotherapy more effective against colon cancer.
A new therapeutic route for combatting treatment-resistant cancer has been identified with the discovery that melanoma cells fight anti-cancer drugs by changing their internal skeleton.
Researchers have discovered that pancreatic cancer cells secrete IL-1β to suppress the immune system and suggest antibody treatments as a therapy for pancreatic ductal adenocarcinoma.
PPP2R2A gene allele deletion in prostate cancers promotes the uncontrolled division of cells, reinstatement of its protein causes cancer cell death, so could provide a new therapeutic option.
A study has demonstrated the success of new compounds that prevent FOXM1, a transcription factor, from increasing cancer proliferation.
A murine study found histone deacetylase 3 (HDAC3) inhibitors reverse epigenetic changes caused by CREBBP mutations found in lymphomas and could be developed into a novel therapy.
A study has shown that the SVC112 molecule can prevent cancer stem cells from producing more tumour cells in cell lines and mice, with no impact on healthy cells.
Modern day oncology therapies have seen significant innovation in the last decade. It is high time we commit to using biomarkers that are driven by rational design and the latest computational methods.
A new study has revealed that the Siah2 protein is crucial to control Tregs in mice, which can reduce the effectiveness of immunotherapies.
